Citius Pharmaceuticals
CTXR
74 hedge funds and large institutions have $17.1M invested in Citius Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 10 closing their positions.
603% more call options, than puts
Call options by funds: $281K | Put options by funds: $40K
0% more funds holding
Funds holding: 74 → 74 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.01% less ownership
Funds ownership: 0.64% → 0.63% (-0.01%)
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
44% less capital invested
Capital invested by funds: $30.4M → $17.1M (-$13.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAS
Wealth Advisory Solutions
Indiianapolis,
Indiana
|
+$147K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$139K |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$106K |
| 4 |
AWA
Arkadios Wealth Advisors
Atlanta,
Georgia
|
+$95.1K |
| 5 |
State Street
Boston,
Massachusetts
|
+$90.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$279K |
| 2 |
Renaissance Technologies
New York
|
-$225K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$167K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$101K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$95.8K |
CTXR Hedge Fund Activity: Q3 2023 in Review
74 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2023, worth a combined $17.1M — down 44% from $30.4M a quarter earlier.
Fund positioning in CTXR was balanced in Q3 2023: 10 funds opened new positions, 10 closed out, 17 added to existing stakes and 18 trimmed.
The largest buyer was Wealth Advisory Solutions, opening a new position worth an estimated $147K. The largest seller was BlackRock, cutting an estimated $279K.
- 74 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $17.1M of Citius Pharmaceuticals stock for Q3 2023, down 44% quarter-over-quarter.
- 10 funds opened new Citius Pharmaceuticals positions in Q3 2023 and 10 closed out, a net change of 0 holders.
- The largest Citius Pharmaceuticals buyer in Q3 2023 was Wealth Advisory Solutions, an estimated $147K added.
- The largest Citius Pharmaceuticals seller in Q3 2023 was BlackRock, an estimated $279K sold.
Based on aggregated 13F filings for Q3 2023.